RGNX
Regenxbio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Market Cap: 1.07 Billion
Primary Exchange: NASDAQ
Website: http://regenxbio.com/
Shares Outstanding: 44.4 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.2919853816782785
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 945 trading days
From: 2018-07-10 To: 2024-03-07
Lowest Point:
REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference
via: PR Newswire at 2019-06-11 03:00:00:000
ROCKVILLE, Md. , June 11,2019 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it will… read more...
REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference
via: PR Newswire at 2019-06-11 03:00:00:000
ROCKVILLE, Md. , June 11,2019 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it will… read more...
REGENXBIO to Present at the Raymond James 2019 Life Sciences and MedTech Conference
via: PR Newswire at 2019-06-11 03:00:00:000
ROCKVILLE, Md. , June 11,2019 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV Technology Platform, today announced it will… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|